All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
acr_session2.jpeg

EULAR 2021 – Day 2 Report

Jack Cush, MD

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well.. It’s time for more personalized approach to PsA treatment! Excellent talk by @DrLauraCoates Abs#OP6937 #EULAR2021 @RheumNow https://t.co/1NKLfmH2y5
Robert B Chao, MD doctorRBC ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl
Robert B Chao, MD doctorRBC ( View Tweet)
#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE
Paul Studenic Stiddyo ( View Tweet)
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Paul Studenic Stiddyo ( View Tweet)
Several domains of disease in #PsA need to be considered. Composite scores have the benefit of providing a summary. What is your favourite composite score for PsA in your clinical practice? #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Fecal Transplantation as Potential PsA Treatment: Dr. Eric Dein ( @ejdein1) #EULAR2021 https://t.co/ItYAEIJZSW https://t.co/uHnY9cWLEj

Links:

Dr. John Cush RheumNow ( View Tweet)
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Dr. Rachel Tate uptoTate ( View Tweet)
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021 https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK

Links:

Dr. John Cush RheumNow ( View Tweet)
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
Aurelie Najm AurelieRheumo ( View Tweet)
Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×